Related content

Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody‐dependent cytotoxicity and improves overall survival against CD20+ rituximab‐sensitive/‐resistant Burkitt lymphoma (BL) and precursor B‐acute lymphoblastic leukaemia (pre‐B‐ALL): potential targeted therapy in patients with poor risk CD20+BL and pre‐B‐ALL

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 171, Iss. 5, 2015-12 ,pp. : 763-775

John Wiley & Sons Inc

Access to resources Recommend Favorite

Expression of CD157 and CD38 Antigens on Human Myeloid Leukaemia Cells: A Similar Pattern of Modulation with Differentiating Inducers

By  

Acta Haematologica, Vol. 105, Iss. 4, 2001-08 ,pp. : 249-251

Karger

Access to resources Recommend Favorite

Advances in targeted therapy for acute myeloid leukaemia

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 180, Iss. 4, 2018-02 ,pp. : 484-500

John Wiley & Sons Inc

Access to resources Recommend Favorite

Change of CD20 Expression in Diffuse Large B-Cell Lymphoma Treated with Rituximab, an Anti-CD20 Monoclonal Antibody: A Study of the Osaka Lymphoma Study Group

By  

Case Reports in Oncology, Vol. 2, Iss. 3, 2009-10 ,pp. : 194-202

Karger

Access to resources Recommend Favorite

Monoclonal antibody therapy for classical Hodgkin lymphoma

By Paszkiewicz-Kozik Ewa   Walewski Jan  

Clinical Investigation, Vol. 3, Iss. 9, 2013-09 ,pp. : 899-910

Future Science

Access to resources Recommend Favorite